Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PRLD
PRLD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRLD News
Prelude Therapeutics Prices 18 Million Share Offering at $4.44 Each
22h ago
Newsfilter
Prelude Therapeutics Prices $90 Million Offering for Oncology Development
1h ago
NASDAQ.COM
Prelude Therapeutics Prices Public Offering at $4.44 per Share
21h ago
seekingalpha
Prelude Therapeutics Appoints New Chief Medical Officer
5d ago
NASDAQ.COM
Prelude Therapeutics Appoints New Chief Medical Officer
5d ago
Newsfilter
Prelude Therapeutics Reports 2025 Results and Pipeline Update
Mar 11 2026
NASDAQ.COM
Prelude Therapeutics Reports FY Earnings with Revenue Surge
Mar 10 2026
seekingalpha
Prelude Therapeutics Receives FDA Clearance for New Drug Application
Mar 10 2026
Newsfilter
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Globenewswire
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Newsfilter
Prelude Therapeutics Receives FDA Clearance for PRT12396 Trials
Feb 03 2026
stocktwits
Prelude Therapeutics Receives FDA Clearance for Blood Cancer Trial
Feb 03 2026
seekingalpha
Prelude Therapeutics Receives FDA Clearance for Phase 1 Study of PRT12396
Feb 03 2026
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for Pelareorep in Colorectal Cancer
Dec 16 2025
Globenewswire
Prelude Therapeutics Unveils JAK2 Inhibitor, Plans IND Filing in Q1 2026
Dec 06 2025
Globenewswire
Show More News
